FOR2240-Logo2FOR2240-Logo2FOR2240-Logo2FOR2240-Logo2
  • Home
  • About
  • Projects
    • P1 Lymph-Transplant
    • P2 Modulators of LA
    • N1 Ocular GvHD
    • N2 ABCB5 & Pterygium
    • P4 Ocular Melanoma
    • P5 Myeloid Cells
    • P6 Microglia in AMD
    • P8 Uveitis
    • C1 Eye Imaging
    • C2 Management
  • Team
    • Executive Board
    • Research Groups
    • Central Projects
    • Associated projects
    • Alumni
  • Publications
  • Links
  • News
✕
Published by Bock on April 12, 2022
Categories
  • DateApril 12, 2022
  • Executive Board
  • Research Groups
  • Central Projects
  • Associated projects
  • Alumni

Curriculum Vitae

Daria Lehrmann

AG Ophthalmo-Onkologie
Gebäude 74, 1.024
Weyertal 115c
Uniklinik Köln
50937 Köln

Tel.: 0221-478 51423
Email: daria.lehrmann@uk-koeln.de

Scientific career

2015 Project “Pharmevolution” Drug development simulation including tasks in synthesis, analytics, pharmaceutical technology, drug screening and quality management, University for Applied Sciences Cologne

2015-2016 Development of a therapeutic vaccine against antigens of pancreatic carcinoma, Internship & Bachelor thesis, CIRES GmbH, Bio-Medical Center Bochum

2018-2019 „The role of ATM kinase in T-cell mediated immune surveillance in lymphoma“, Master thesis, University Hospital Cologne, Reinhardt Lab (DNA damage response)

2019-present “Identification of novel potential targets in angiogenesis and metastasis in uveal melanoma“, Doctoral thesis, University Hospital Cologne, Heindl lab (Ophthalmological Oncology)

Selected publications

Lehrmann, D., Refaian, N., Simon, M., Rokohl, A., & Heindl, L. (2022). Preclinical models in ophthalmic oncology—a narrative review. Annals Of Eye Science, 7, 14. doi:10.21037/aes-21-39

Riabinska A, Lehrmann D, Jachimowicz RD, et al. ATM activity in T cells is critical for immune surveillance of lymphoma in vivo. Leukemia. 2020;34(3):771-786. doi:10.1038/s41375-019-0618-2 (Impact factor: 11.528)

More information

  • Publication highlights
  • Jobs
  • Contact
  • Impressum
  • Datenschutz

Newest publications

Supplemental Anti Vegf A-Therapy Prevents Rebound…(2020)


Bevacizumab Induces Upregulation of Keratin 3 and VEGFA in Human…(2020)


Immune reactions after modern lamellar (DALK, DSAEK, DMEK) versus conventional…(2020)


Contact

Claudia Bock
Management Office
DFG Research Unit FOR2240
Department of Ophthalmology
University of Cologne
Kerpener Str. 62
50937 Cologne, Germany

www.for2240.de

Tel. +49 (0)221 478 32845
Fax. +49 (0)221 478 5094
claudia.bock@uk-koeln.de

Partnerlogos

© 2021 FOR2240 | Online Marketing von Resulted Lübeck
      Um unsere Website für Sie optimal zu gestalten und fortlaufend verbessern zu können, verwenden wir Cookies. Durch die weitere Nutzung der Webseite stimmen Sie der Verwendung von Cookies zu. Weitere Informationen zu Cookies und insb. der Möglichkeiten, der Verwendung von Cookies zu widersprechen, erhalten Sie in unserer Datenschutzerklärung.SchließenDatenschutzerklärung